Skip to main
CVAC
CVAC logo

CureVac B.V (CVAC) Stock Forecast & Price Target

CureVac B.V (CVAC) Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

CureVac NV is positioned favorably within the competitive mRNA market, which benefits from high demand stemming from COVID-19 vaccines and the anticipated broader applications of mRNA technology. The company's collaboration with GSK on developing second-generation vaccines for seasonal influenza and COVID-19, as well as an avian influenza vaccine, underscores its innovative approach and strategic partnerships in the vaccine space. Furthermore, CureVac's ongoing development of a diverse pipeline, including mRNA vaccines for oncology and therapies targeting various diseases, highlights its commitment to advancing cutting-edge solutions that could enhance patient outcomes.

Bears say

CureVac NV is expected to continue incurring significant net losses until product approval and commercialization, raising concerns about its financial sustainability in the interim. The company faces substantial competitive risks, as it may struggle to effectively compete against both established players and other in-development candidates in the mRNA vaccine market. Additionally, potential legal and intellectual property challenges could adversely affect CureVac's market position and overall sales, further contributing to the negative outlook on its stock.

CureVac B.V (CVAC) has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CureVac B.V and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CureVac B.V (CVAC) Forecast

Analysts have given CureVac B.V (CVAC) a Hold based on their latest research and market trends.

According to 3 analysts, CureVac B.V (CVAC) has a Hold consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CureVac B.V (CVAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.